Real-World Safety of Esketamine Nasal Spray: A Comprehensive Analysis of Esketamine and Respiratory Depression. [PDF]
Int J NeuropsychopharmacolAbstract Background Esketamine nasal spray (ESK) is approved, in conjunction with an oral antidepressant, for the treatment of treatment-resistant depression in adults and for the treatment of depressive symptoms in adults with major depressive disorder with acute suicidal ideation or behavior.
Chepke C +5 more
europepmc +5 more sources
Managing dissociative symptoms following the use of esketamine nasal spray: a case report. [PDF]
Int Clin Psychopharmacol, 2021 Patients with treatment-resistant depression (TRD) treated with esketamine nasal spray commonly experience transient symptoms of dissociation. Manifestations of dissociation, such as feelings of detachment from the environment, can cause considerable anxiety for patients.
Pereira S +5 more
europepmc +6 more sources
Relationship Between Dissociation and Antidepressant Effects of Esketamine Nasal Spray in Patients With Treatment-Resistant Depression. [PDF]
Int J Neuropsychopharmacol, 2022 Abstract Background In this post-hoc analysis, data from 2 positive, pivotal, phase 3 trials of esketamine nasal spray (ESK) in treatment-resistant depression (TRD)—short-term study (TRANSFORM-2) and maintenance study (SUSTAIN-1)—were analyzed to evaluate the relationship between dissociation and ...
Chen G +11 more
europepmc +6 more sources
Frontiers in PharmacologyEsketamine nasal spray (ESK-NS) is a new drug for treatment-resistant depression, and we aimed to detect and characterize the adverse events (AEs) of ESK-NS using the Food and Drug Administration (FDA) adverse event reporting system (FAERS) database ...
Ruixue Liu +4 more
doaj +5 more sources
Early Clinical Experiences of Esketamine Nasal Spray in the UK in Adults with Treatment-Resistant Major Depressive Disorder: Advisory Panel Recommendations [PDF]
Neuropsychiatric Disease and Treatment, 2023 Allan H Young,1 Mohamed Abdelghani,2 Mario F Juruena,1,3 Viktoriya L Nikolova,1 Ramin Nilforooshan4,5 1Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, UK; 2Camden and Islington NHS Foundation Trust, London, UK ...
Young AH +4 more
doaj +2 more sources
Esketamine: new hope for the treatment of treatment-resistant depression? A narrative review [PDF]
Therapeutic Advances in Drug Safety, 2020 This narrative review aims to provide an overview of the current literature on the pharmacology, safety, efficacy and tolerability of intranasal esketamine, the S-enantiomer of ketamine, for the treatment of treatment-resistant depression (TRD).
Mohammed S Salahudeen +2 more
doaj +3 more sources
ESKALE study, a French real-world study describing TRD patients with Esketamine nasal spray: final analysis [PDF]
European Psychiatry, 2023 Introduction Treatment resistant depression (TRD) affects a substantial proportion of patients with depression and carries a large unmet need. Esketamine nasal spray (NS), in combination with a selective serotonin reuptake inhibitor (SSRI) or serotonin ...
L. Samalin +5 more
doaj +2 more sources
A real-world pharmacovigilance study of esketamine nasal spray. [PDF]
Medicine (Baltimore)Mining and updating the post-marketing safety signals of esketamine nasal spray for better identification of adverse drug event (ADE) signals and medication monitoring during clinical use to ensure patient medication safety. Downloading data from the US Food and Drug Administration Adverse Event Reporting System from Q1 2019 to Q2 2023, the reporting ...
Chen Y, Gu H, Li W, Chen Y.
europepmc +4 more sources
ICEBERG study: an indirect adjusted comparison estimating the long-term benefit of esketamine nasal spray when compared with routine treatment of treatment resistant depression in general psychiatry [PDF]
Frontiers in Psychiatry, 2023 BackgroundTreatment resistant depression (TRD) affects 10–30% of patients with major depressive disorder. In 4-week trials, esketamine nasal spray (NS) was efficacious vs.
Albino J. Oliveira-Maia +8 more
doaj +2 more sources
Esketamine in Treatment-Resistant Depression and Suicidal Ideation: A Systematic Review [PDF]
Journal of Education, Health and SportBackground. Major depressive disorder affects 20% of the global population, with treatment-resistant depression in 10-30% of cases. Patients with acute suicidal ideation need immediate intervention, yet conventional antidepressants require weeks to work.
Natalia Dudziak +8 more
doaj +3 more sources